In patients with homozygous familial hypercholesterolaemia (HoFH) receiving maximum doses of lipid-lowering therapy, evinacumab reduced LDL-cholesterol (LDL-C) by 47.1% at week 24, compared to an increase of 1.9% with placebo.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
